...
scyx-img

Scynexis Inc, Common Stock

SCYX

NMQ

$1.14

+$0.03

(2.7%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$44.77M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
170.57K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.50
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.11 L
$3.07 H
$1.14

About Scynexis Inc, Common Stock

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameSCYXSectorS&P500
1-Week Return-5%-2.27%-0.57%
1-Month Return-11.63%-3.96%1.21%
3-Month Return-21.92%-9.7%7.57%
6-Month Return-46.48%-3.37%11.45%
1-Year Return-31.74%3.71%28.48%
3-Year Return-84.45%3.8%29.52%
5-Year Return-84.38%39.78%90.66%
10-Year Return-98.86%106.91%203.75%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue121.00K12.05M13.16M5.09M140.14M[{"date":"2019-12-31","value":0.09,"profit":true},{"date":"2020-12-31","value":8.6,"profit":true},{"date":"2021-12-31","value":9.39,"profit":true},{"date":"2022-12-31","value":3.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue-303.00K312.00K628.00K15.62M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":1.94,"profit":true},{"date":"2021-12-31","value":2,"profit":true},{"date":"2022-12-31","value":4.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit121.00K(303.00K)12.85M4.46M124.52M[{"date":"2019-12-31","value":0.1,"profit":true},{"date":"2020-12-31","value":-0.24,"profit":false},{"date":"2021-12-31","value":10.32,"profit":true},{"date":"2022-12-31","value":3.58,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin100.00%(2.51%)97.63%87.66%88.85%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-2.51,"profit":false},{"date":"2021-12-31","value":97.63,"profit":true},{"date":"2022-12-31","value":87.66,"profit":true},{"date":"2023-12-31","value":88.85,"profit":true}]
Operating Expenses49.04M50.81M73.68M90.22M51.85M[{"date":"2019-12-31","value":54.36,"profit":true},{"date":"2020-12-31","value":56.32,"profit":true},{"date":"2021-12-31","value":81.66,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":57.47,"profit":true}]
Operating Income(48.92M)(51.15M)(60.83M)(85.76M)72.67M[{"date":"2019-12-31","value":-67.32,"profit":false},{"date":"2020-12-31","value":-70.39,"profit":false},{"date":"2021-12-31","value":-83.7,"profit":false},{"date":"2022-12-31","value":-118.01,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(6.14M)(9.38M)20.95M12.88M(9.66M)[{"date":"2019-12-31","value":-29.32,"profit":false},{"date":"2020-12-31","value":-44.77,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":61.48,"profit":true},{"date":"2023-12-31","value":-46.11,"profit":false}]
Pre-Tax Income(53.71M)(58.33M)(35.95M)(67.51M)67.18M[{"date":"2019-12-31","value":-79.95,"profit":false},{"date":"2020-12-31","value":-86.83,"profit":false},{"date":"2021-12-31","value":-53.52,"profit":false},{"date":"2022-12-31","value":-100.49,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes1.52M(3.15M)(3.09M)(4.70M)138.00K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-206.56,"profit":false},{"date":"2021-12-31","value":-202.62,"profit":false},{"date":"2022-12-31","value":-308.4,"profit":false},{"date":"2023-12-31","value":9.06,"profit":true}]
Income After Taxes(55.23M)(55.19M)(32.87M)(62.81M)67.04M[{"date":"2019-12-31","value":-82.39,"profit":false},{"date":"2020-12-31","value":-82.32,"profit":false},{"date":"2021-12-31","value":-49.02,"profit":false},{"date":"2022-12-31","value":-93.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(53.71M)(55.19M)(32.87M)(62.81M)72.20M[{"date":"2019-12-31","value":-74.39,"profit":false},{"date":"2020-12-31","value":-76.44,"profit":false},{"date":"2021-12-31","value":-45.52,"profit":false},{"date":"2022-12-31","value":-87,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(55.23M)(55.19M)(32.87M)(62.81M)67.04M[{"date":"2019-12-31","value":-82.39,"profit":false},{"date":"2020-12-31","value":-82.32,"profit":false},{"date":"2021-12-31","value":-49.02,"profit":false},{"date":"2022-12-31","value":-93.69,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)(9.20)(5.15)(1.19)(1.47)1.32[{"date":"2019-12-31","value":-696.97,"profit":false},{"date":"2020-12-31","value":-390.15,"profit":false},{"date":"2021-12-31","value":-90.15,"profit":false},{"date":"2022-12-31","value":-111.36,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SCYX
Cash Ratio 2.68
Current Ratio 3.13

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SCYX
ROA (LTM) -26.72%
ROE (LTM) -48.42%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SCYX
Debt Ratio Lower is generally better. Negative is bad. 0.41
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.59

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SCYX
Trailing PE NM
Forward PE 1.45
P/S (TTM) 5.23
P/B 0.72
Price/FCF 59
EV/R 0.44
EV/Ebitda 0.05
PEG NM

FAQs

What is Scynexis Inc share price today?

Scynexis Inc (SCYX) share price today is $1.14

Can Indians buy Scynexis Inc shares?

Yes, Indians can buy shares of Scynexis Inc (SCYX) on Vested. To buy Scynexis Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SCYX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Scynexis Inc be purchased?

Yes, you can purchase fractional shares of Scynexis Inc (SCYX) via the Vested app. You can start investing in Scynexis Inc (SCYX) with a minimum investment of $1.

How to invest in Scynexis Inc shares from India?

You can invest in shares of Scynexis Inc (SCYX) via Vested in three simple steps:

  • Click on Sign Up or Invest in SCYX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Scynexis Inc shares
What is Scynexis Inc 52-week high and low stock price?

The 52-week high price of Scynexis Inc (SCYX) is $3.07. The 52-week low price of Scynexis Inc (SCYX) is $1.11.

What is Scynexis Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Scynexis Inc (SCYX) is

What is Scynexis Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Scynexis Inc (SCYX) is 0.72

What is Scynexis Inc dividend yield?

The dividend yield of Scynexis Inc (SCYX) is 0.00%

What is the Market Cap of Scynexis Inc?

The market capitalization of Scynexis Inc (SCYX) is $44.77M

What is Scynexis Inc’s stock symbol?

The stock symbol (or ticker) of Scynexis Inc is SCYX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top